Now showing items 1-5 of 5

    • Chronic Lymphocytic Leukemia: New Concepts for Future Therapy 

      Dearden, Claire (CIG MEDIA GROUP, LP, 2010-10)
      Over the past several years, we have witnessed rapid advances in our understanding of the biology and treatment of chronic lymphocytic leukemia (CLL). New prognostic factors have been characterized that help identify ...
    • High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H 

      Dearden, CE; Matutes, E; Cazin, B; Tjonnfjord, GE; Parreira, A; Nomdedeu, B; Leoni, P; Clark, FJ; Radia, D; Rassam, SMB; Roques, T; Ketterer, N; Brito-Babapulle, V; Dyer, MJS; Catovsky, D (AMER SOC HEMATOLOGY, 2001-09-15)
      T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. ...
    • How I treat prolymphocytic leukemia 

      Dearden, Claire (2012-07)
      T- and B-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphologic, immunophenotypic, cytogenetic, and molecular features. Recent studies have highlighted the ...
    • Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia 

      Dearden, Claire (2014-07)
      Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated ...
    • Role of antibody therapy in lymphoid malignancies 

      Dearden, Claire (2007)
      Introduction: Over the past decade, the potential for delivering targeted therapy against malignant disease by the use of monoclonal antibodies (MoAbs) has begun to be realized. The development of human or chimeric antibodies ...